Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease

Amprion and Modality.AI announce partnership to explore how molecular biomarkers and AI-enabled digital assessments can be combined to improve the characterization of neurodegenerative diseases

1upHealth Announces 1up Gateway to Simplify CMS-0057-F Compliance for Health Plans

1upHealth launches the 1up Gateway to support compliance with the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) among health plans with existing FHIR infrastructure. With this new release, 1upHealth is ensuring the broader payer ecosystem is prepared for interoperability regulations ahead of the final January 1, 2027 deadline.

Novartis to Acquire Myricx Bio in USD 1.5 Billion Deal, Strengthening Next-Generation ADC Cancer Pipeline

Novartis has agreed to acquire UK-based biotech company Myricx Bio in a deal worth up to USD 1.5 billion to strengthen its oncology pipeline. The acquisition brings Myricx's next-generation NMTi antibody-drug conjugate (ADC) platform, designed to overcome resistance to existing cancer therapies. It also adds two lead ADC candidates targeting B7-H3 and HER2, expanding Novartis' portfolio for treating solid tumors. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.

VisualDx Partners with Sun River Health to Expand Access to Clinical Decision Support for Underserved Patients

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

New proprietary capability enhances ProPharma’s regulatory service delivery model, helping clients accelerate submission development while maintaining the highest standards of quality and compliance.

CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM

New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing the industry’s first quantitative business case for risk-based oversight in clinical development

FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Engineering, Cybersecurity and AI

ECI has announced the appointment of Taranjit S. Samra, DRSc, MSEE, RAC, as Head of Medical Device Software Engineering, Cybersecurity and AI.

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

eClinical Solutions Advances Risk-Based Quality Management Solutions, Helping Sponsors Meet ICH E6(R3) Regulatory Guidelines

Enhancements further break down silos and reduce fragmentation through integrated risk and quality management within one clinical data intelligence platform

Sunnen Products Company Highlights the PGE-6000 Gage with Advanced Precision for Medical Applications

Cutting-Edge Bore Gaging System Offers Unmatched Precision, Versatility, and Efficiency for High-Precision Measurement Needs in Medical Device Manufacturing

Symeres and Axxam Appoint Russell Thomas as Chief Scientific Officer to lead their collaborative integrated discovery platform

Terrestrial Doses First Patients in Phase 1 Clinical Trial of Tacterra™ Microarray Patch for Semaglutide Delivery

Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, today announced it has dosed its first patients in the company's Phase 1 clinical trial evaluating VX-201, a needle-free microarray patch (MAP) that delivers semaglutide.

ZoBio launches comprehensive DEL hit discovery service for challenging targets

Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent Automation

Aylward Enterprises Highlights Cube Feed System for High-Speed Solid-Dose Blister Packaging

Servo-driven blister feed technology delivers precise product placement, flexible format handling, and seamless integration with continuous and intermittent blister machines

Revecore Launches ReClaim(TM), an AI-Native Platform Built for the Complexity Modern Hospitals Face

Ambience Healthcare Introduces Nursing Suite to Extend System of Intelligence Across Inpatient Nursing

ZeOmega Earns HITRUST CSF® Certification through DirectTrust®

Eli Lilly Launches National Sleep Apnea Awareness Campaign with Shaquille O'Neal and Zepbound

Eli Lilly has launched a nationwide awareness campaign featuring basketball legend Shaquille O'Neal to highlight the risks of moderate-to-severe obstructive sleep apnea (OSA). After learning that years of fatigue, loud snoring, and poor sleep were symptoms of OSA, O'Neal began treatment with Zepbound® (tirzepatide). The campaign encourages people experiencing sleep apnea symptoms to seek medical advice and explore treatment options. Zepbound is the first FDA-approved prescription medicine for adults with obesity and moderate-to-severe OSA, helping improve sleep quality and reduce breathing interruptions during sleep.